Clinical trial
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
NCT02101268 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 19, 2014
- Completion date
- April 25, 2019
- Enrollment
- 156 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.
post-essential thrombocythemia myelofibrosis (post-et mf), post-polycythemia vera (post-pv), primary myelofibrosis (pmf)